Combining Doxil, Carboplatin, and Paclitaxel for Ovarian Cancer
Author Information
Author(s): Gibbs D D, Pyle L, Allen M, Vaughan M, Webb A, Johnston S R D, Gore M E
Primary Institution: The Royal Marsden Hospital
Hypothesis
Can the combination of pegylated liposomal doxorubicin, carboplatin, and paclitaxel improve treatment outcomes in ovarian cancer?
Conclusion
The study established safe dosage levels for a combination treatment of doxil, carboplatin, and paclitaxel in ovarian cancer patients.
Supporting Evidence
- The maximum tolerated dose was defined as carboplatin AUC 5, paclitaxel 175 mg/m², and doxil 30 mg/m².
- 67% of patients showed antitumor effects with the treatment.
- CA125 response rate was 87% among patients with measurable disease.
Takeaway
Doctors tested a new mix of medicines to help women with ovarian cancer, and they found safe amounts to use.
Methodology
Patients received doxil, followed by carboplatin and then paclitaxel, with dose adjustments based on toxicity.
Limitations
The study was not designed to assess efficacy, and the sample size was small.
Participant Demographics
The median age of participants was 54 years, with most having advanced disease.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website